Gilead Sciences : GILD

All Gilead Sciences Articles

734 Articles

Trey Thoelcke | Feb 26, 2014 at 8:25 AM EST

Six New Stocks to Buy in the Piper Jaffray Model Portfolio

Most Wall Street firms run model portfolios for their institutional and retail clients. Here are stocks that recently were added…

Trey Thoelcke | Feb 24, 2014 at 8:20 AM EST

Deutsche Bank Unveils Its “What to Buy Now?” List

In a new research report, the analysts at Deutsche Bank unveil their "what to buy now ?" list for large…

Jon C. Ogg | Feb 13, 2014 at 10:40 AM EST

Top Pharma and Biotech Stocks to Buy From Key Investor Conference

With top biotechnology and health care companies from around the world attending the Leerink Global Healthcare, it is a good…

Trey Thoelcke | Feb 12, 2014 at 6:50 AM EST

Short Sellers Shy Away From Biotechs

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. By and large, short sellers…

Jon C. Ogg | Feb 10, 2014 at 3:20 PM EST

Gilead Going to $90, or $110

ThinkstockGilead Sciences Inc. (NASDAQ: GILD) is rising on Monday after two analysts made positive calls on the biotech giant. As…

Jon C. Ogg | Feb 10, 2014 at 8:25 AM EST

Top Analyst Upgrades and Downgrades: Fairway Group, J.P. Morgan, Red Robin, Vodafone, More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on is Monday, February 10,…

Jon C. Ogg | Feb 4, 2014 at 4:29 PM EST

Despite Size, Gilead Keeps Growing and Growing

ThinkstockGilead Sciences Inc. (NASDAQ: GILD) is the biggest biotech company in America, and it is one of the top performers…

cgblaine22 | Jan 29, 2014 at 12:10 PM EST

Why Caution Is Prevailing in Biotechs Into and After Earnings

Biogen Idec surprised investors Wednesday with weaker-than-expected guidance for 2014 earnings. Amgen beat estimates late Tuesday. Celgene and Gilead Sciences…

Trey Thoelcke | Jan 29, 2014 at 8:15 AM EST

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large…

Jon C. Ogg | Jan 8, 2014 at 8:10 AM EST

J.P. Morgan Top Biotechnology Stocks to Buy for 2014

Biotechnology was an incredible performer in 2013. The analysts at J.P. Morgan think that the huge outperformance may lessen going…

Trey Thoelcke | Jan 2, 2014 at 8:20 AM EST

UBS Top High Conviction Stock Picks for 2014

The U.S. equity strategy team at UBS has a positive view on stocks heading into 2014, particularly technology, financials and…

Jon C. Ogg | Dec 30, 2013 at 8:50 AM EST

Top Analyst Upgrades and Downgrades: Gilead, Teva, Textura, Twitter and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Monday, December 30, 2013.

Trey Thoelcke | Dec 19, 2013 at 8:30 AM EST

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

The Cowen biotechnology team has a list of top 10 surprises that are specific to the very hot biotechnology sector.

Jon C. Ogg | Dec 18, 2013 at 8:20 AM EST

Piper Jaffray Top Stocks to Buy for 2014

courtesy of Apple Inc.Like most firms that we cover on Wall Street, Piper Jaffray has updated its top names to…

Lee Jackson | Dec 11, 2013 at 9:00 AM EST

Credit Suisse Offers Top Biotech Stocks to Buy for 2014

ThinkstockCredit Suisse is out and pounding the table that biotechnology cannot be ignored in 2014. Biotech has been the top-performing…

1 … 38 39 40 41 42 … 49

Gilead Sciences : GILD

All Gilead Sciences Articles

Six New Stocks to Buy in the Piper Jaffray Model Portfolio

Deutsche Bank Unveils Its “What to Buy Now?” List

Top Pharma and Biotech Stocks to Buy From Key Investor Conference

Short Sellers Shy Away From Biotechs

Gilead Going to $90, or $110

Top Analyst Upgrades and Downgrades: Fairway Group, J.P. Morgan, Red Robin, Vodafone, More

Despite Size, Gilead Keeps Growing and Growing

Why Caution Is Prevailing in Biotechs Into and After Earnings

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

J.P. Morgan Top Biotechnology Stocks to Buy for 2014

UBS Top High Conviction Stock Picks for 2014

Top Analyst Upgrades and Downgrades: Gilead, Teva, Textura, Twitter and More

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

Piper Jaffray Top Stocks to Buy for 2014

Credit Suisse Offers Top Biotech Stocks to Buy for 2014

Silver and Copper Are Outpacing Gold in 2026 and After Following Industrial Metals These 3 ETFs Show How Smart Money Is Playing the Trend

At 65, Your HSA Stops Being a Medical Account and Starts Beating Your 401(k)

Lower Your Mortgage Payment Without Refinancing, Without Closing Costs, and Without a Credit Check

At 65, Your HSA Stops Being a Medical Account and Starts Beating Your 401(k)

Lower Your Mortgage Payment Without Refinancing, Without Closing Costs, and Without a Credit Check

Silver and Copper Are Outpacing Gold in 2026 and After Following Industrial Metals These 3 ETFs Show How Smart Money Is Playing the Trend

At 65, Your HSA Stops Being a Medical Account and Starts Beating Your 401(k)

Gilead Sciences : GILD

All Gilead Sciences Articles

Six New Stocks to Buy in the Piper Jaffray Model Portfolio

Deutsche Bank Unveils Its “What to Buy Now?” List

Top Pharma and Biotech Stocks to Buy From Key Investor Conference

Short Sellers Shy Away From Biotechs

Gilead Going to $90, or $110

Top Analyst Upgrades and Downgrades: Fairway Group, J.P. Morgan, Red Robin, Vodafone, More

Despite Size, Gilead Keeps Growing and Growing

Why Caution Is Prevailing in Biotechs Into and After Earnings

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

J.P. Morgan Top Biotechnology Stocks to Buy for 2014

UBS Top High Conviction Stock Picks for 2014

Top Analyst Upgrades and Downgrades: Gilead, Teva, Textura, Twitter and More

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

Piper Jaffray Top Stocks to Buy for 2014

Credit Suisse Offers Top Biotech Stocks to Buy for 2014

Silver and Copper Are Outpacing Gold in 2026 and After Following Industrial Metals These 3 ETFs Show How Smart Money Is Playing the Trend

At 65, Your HSA Stops Being a Medical Account and Starts Beating Your 401(k)

Lower Your Mortgage Payment Without Refinancing, Without Closing Costs, and Without a Credit Check

Featured Reads

At 65, Your HSA Stops Being a Medical Account and Starts Beating Your 401(k)

Lower Your Mortgage Payment Without Refinancing, Without Closing Costs, and Without a Credit Check